A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma
Por:
Moreau, P, Parmar, G, Prince, M, Ocio, E, Karenes, C, Madan, S, Oriol, A, Bories, P, Delforge, M, Galbrail, N, Semiond, D, Jia, N, Mace, S, Suzan, F and van de Velde, H
Publicada:
1 oct 2021
Resumen:
Filiaciones:
Moreau, P:
Univ Hosp Hotel Dieu, Paris, France
Parmar, G:
Illawarra Canc Care Ctr, Wollongong, NSW, Australia
Prince, M:
Epworth Healthcare, Melbourne, Vic, Australia
Univ Melbourne, Melbourne, Vic, Australia
Ocio, E:
Univ Cantabria, Santander, Spain
Karenes, C:
City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
Madan, S:
Banner MD Anderson Canc Ctr, Houston, TX USA
:
Hosp Badalona Germans Trias & Pujol, Inst Recerca Leucemia Josep Carreras, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain
Bories, P:
Reseau Reg Cancerol Oncooccitanie, Toulouse, France
Delforge, M:
Univ Hosp Leuven, Leuven, Belgium
Galbrail, N:
Gabrail Canc Ctr, Canton, OH USA
Semiond, D:
Sanofi, Vitry Sur Seine, France
Jia, N:
Sanofi, Vitry Sur Seine, France
Mace, S:
Sanofi, Vitry Sur Seine, France
Suzan, F:
Sanofi, Vitry Sur Seine, France
van de Velde, H:
Sanofi, Cambridge, MA USA
|